Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.45 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.45 |
| ▸ | UGCG | Q16739 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114487 | 0.90 | KCNH2 (0.53) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2117151 | 0.89 | RAB9A (0.55) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2113273 | 0.89 | L3MBTL1 (0.59) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2111927 | 0.87 | L3MBTL1 (0.51) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2115661 | 0.86 | MEN1 (0.51) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2114247 | 0.86 | MAPT (0.52) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2112892 | 0.86 | L3MBTL1 (0.52) | MEN1KMT2AGRM5TSHRNPC1 | |
| SCHEMBL2113550 | 0.85 | RAB9A (0.55) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL27923486 | 0.85 | TDP1 (0.57) | MEN1KMT2ATSHRNPC1SMN1; SMN2 | |
| SCHEMBL2115920 | 0.83 | SMN1; SMN2 (0.58) | MEN1KMT2ATSHRNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | claimed |
| CN-103153957-B | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMAN-LA ROCHE LTD. (CH) | 2016-01-20 | — | — | CN | claimed |
| EP-2627637-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2013-08-21 | — | — | EP | claimed |
| CN-103153957-A | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | claimed |
| WO-2012049190-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | WO | claimed |
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| CN-103153957-B | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMAN-LA ROCHE LTD. (CH) | 2016-01-20 | — | — | CN | disclosed |
| EP-2627637-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-103153957-A | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN LA ROCHE | 2013-06-12 | — | — | CN | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| WO-2012049190-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | APOB, CETP, NPC1L1 | MEN1 1838/4885KMT2A 1813/4885GRM5 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.